Resistance profiling of Aspergillus fumigatus to olorofim indicates absence of intrinsic resistance and unveils the molecular mechanisms of acquired olorofim resistance

References

• Bongomin F, Gago S, Oladele RO, et al. Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi. 2017 Oct 18;3(4):E57.
   Web of Science ®Google Scholar
• van de Veerdonk FL, Kolwijck E, Lestrade PP, et al. Influenza-associated aspergillosis in critically ill patients. Am J Respir Crit Care Med. 2017 Aug 15;196(4):524–527.
   PubMed Web of Science ®Google Scholar
• Schauwvlieghe A, Rijnders BJA, Philips N, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018 Oct;6(10):782–792.
   PubMed Web of Science ®Google Scholar
• White PL, Dhillon R, Cordey A, et al. A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU. Clin Infect Dis. 2020 Aug 29;73(7):e1634–e1644.
   Web of Science ®Google Scholar
• Lamoth F, Glampedakis E, Boillat-Blanco N, et al. Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients. Clin Microbiol Infect. 2020 Jul 10;26(12):1706–1708.
   PubMed Web of Science ®Google Scholar
• Dupont D, Menotti J, Turc J, et al. Pulmonary aspergillosis in critically ill patients with Coronavirus disease 2019 (COVID-19). Med Mycol. 2020 Sep 10;59(1):110–114.
   Web of Science ®Google Scholar
• Patterson TF, Thompson GR, 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016 Aug 15;63(4):e1–e60.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018 May;24(Suppl 1):e1–e38.
   PubMed Web of Science ®Google Scholar
• Aruanno M, Glampedakis E, Lamoth F. Echinocandins for the treatment of invasive aspergillosis: from laboratory to bedside. Antimicrob Agents Chemother. 2019 Aug;63(8):e00399–19.
   PubMed Web of Science ®Google Scholar
• Adler-Moore J, Lewis RE, Brüggemann RJM, et al. Preclinical safety, tolerability, pharmacokinetics, pharmacodynamics, and antifungal activity of liposomal amphotericin B. Clin Infect Dis. 2019 May 2;68(Suppl 4):S244–s259.
   PubMed Web of Science ®Google Scholar
• Verweij PE, Chowdhary A, Melchers WJ, et al. Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles? Clin Infect Dis. 2016 Feb 01;62(3):362–368.
   PubMed Web of Science ®Google Scholar
• Buil JB, Snelders E, Denardi LB, et al. Trends in azole resistance in Aspergillus fumigatus, the Netherlands, 1994–2016. Emerg Infect Dis. 2019 Jan;25(1):176–178.
   PubMed Web of Science ®Google Scholar
• Lestrade PPA, Buil JB, van der Beek MT, et al. Paradoxal trends in azole-resistant Aspergillus fumigatus in a national multicenter surveillance program, the Netherlands, 2013–2018. Emerg Infect Dis. 2020 Jul;26(7):1447–1455.
   PubMed Web of Science ®Google Scholar
• Lestrade PP, Bentvelsen RG, Schauwvlieghe A, et al. Voriconazole resistance and mortality in invasive aspergillosis: a multicenter retrospective Cohort study. Clin Infect Dis. 2019 Apr 24;68(9):1463–1471.
   PubMed Web of Science ®Google Scholar
• Verweij PE, Snelders E, Kema GH, et al. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis. 2009 Dec;9(12):789–795.
   PubMed Web of Science ®Google Scholar
• Jones ME. Pyrimidine nucleotide biosynthesis in animals: genes, enzymes, and regulation of UMP biosynthesis. Annu Rev Biochem. 1980;49:253–279.
   PubMed Web of Science ®Google Scholar
• Oliver JD, Sibley GE, Beckmann N, et al. F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. Proc Natl Acad Sci USA. 2016 Oct 25;113(45):12809–12814.
   PubMed Web of Science ®Google Scholar
• Astvad KMT, Jørgensen KM, Hare RK, et al. Olorofim susceptibility testing of 1423 Danish mould isolates 2018–2019 confirms uniform and broad-spectrum activity. Antimicrob Agents Chemother. 2020 Oct 5;65(1):e01527–20.
   PubMed Web of Science ®Google Scholar
• du Pré S, Beckmann N, Almeida MC, et al. Effect of the novel antifungal drug F901318 (olorofim) on growth and viability of Aspergillus fumigatus. Antimicrob Agents Chemother. 2018;62(8):e00231-18.
   PubMed Web of Science ®Google Scholar
• Jørgensen KM, Astvad KMT, Hare RK, et al. EUCAST determination of olorofim (F901318) susceptibility of mold species, method validation, and MICs. Antimicrob Agents Chemother. 2018;62(8):e00487–18.
   PubMed Web of Science ®Google Scholar
• Seyedmousavi S, Chang YC, Law D, et al. Efficacy of olorofim (F901318) against Aspergillus fumigatus, A. nidulans, and A. tanneri in murine models of profound neutropenia and chronic granulomatous disease. Antimicrob Agents Chemother. 2019;63(6):e00129-19.
   PubMed Web of Science ®Google Scholar
• Buil JB, Rijs A, Meis JF, et al. In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates. J Antimicrob Chemother. 2017 Sep 1;72(9):2548–2552.
   PubMed Web of Science ®Google Scholar
• Rivero-Menendez O, Cuenca-Estrella M, Alastruey-Izquierdo A. In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies. J Antimicrob Chemother. 2019;74(6):1586–1590.
   PubMed Web of Science ®Google Scholar
• Negri CE, Johnson A, McEntee L, et al. Pharmacodynamics of the novel antifungal agent F901318 for Acute Sinopulmonary Aspergillosis caused by Aspergillus flavus. J Infect Dis. 2018;217(7):1118–1127.
   PubMed Web of Science ®Google Scholar
• Hope WW, McEntee L, Livermore J, et al. Pharmacodynamics of the orotomides against Aspergillus fumigatus: new opportunities for treatment of multidrug-resistant fungal disease. mBio. 2017;8(4):e01157-17.
   PubMed Web of Science ®Google Scholar
• Kirchhoff L, Dittmer S, Buer J, et al. In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus. Int J Antimicrob Agents. 2020 Sep;56(3):106105.
   PubMed Web of Science ®Google Scholar
• Kirchhoff L, Dittmer S, Weisner AK, et al. Antibiofilm activity of antifungal drugs, including the novel drug olorofim, against Lomentospora prolificans. J Antimicrob Chemother. 2020 Aug 1;75(8):2133–2140.
   PubMed Web of Science ®Google Scholar
• Rivero-Menendez O, Cuenca-Estrella M, Alastruey-Izquierdo A. In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies. J Antimicrob Chemother. 2020 Aug 28;75(12):3582–3585.
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Law D, Birch M. Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans. J Antimicrob Chemother. 2017 Mar 15;72(7):1977–1980.
   PubMed Web of Science ®Google Scholar
• Biswas C, Law D, Birch M, et al. In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi. Med Mycol. 2018;56(8):1050–1054.
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Najvar LK, Jaramillo R, et al. The orotomide olorofim is efficacious in an experimental model of central nervous system coccidioidomycosis. Antimicrob Agents Chemother. 2018;62(9):e00999–18.
   PubMed Web of Science ®Google Scholar
• Lim W, Eadie K, Konings M, et al. Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim. J Antimicrob Chemother. 2020 Apr 1;75(4):936–941.
   PubMed Web of Science ®Google Scholar
• Wiederhold NP. Review of the novel investigational antifungal olorofim. J Fungi. 2020 Jul 30;6(3):122.
   Web of Science ®Google Scholar
• Singh A, Singh P, Meis JF, et al. In vitro activity of the novel antifungal olorofim against dermatophytes and opportunistic moulds including Penicillium and Talaromyces species. J Antimicrob Chemother. 2021 Apr 13;76(5):1229–1233.
   PubMed Web of Science ®Google Scholar
• Badali H, Cañete-Gibas C, Patterson H, et al. In vitro activity of olorofim against clinical isolates of the Fusarium oxysporum and Fusarium solani species complexes. Mycoses. 2021 Jul;64(7):748–752.
   PubMed Web of Science ®Google Scholar
• Lackner M, Birch M, Naschberger V, et al. Dihydroorotate dehydrogenase inhibitor olorofim exhibits promising activity against all clinically relevant species within Aspergillus section Terrei. J Antimicrob Chemother. 2018;73(11):3068–3073.
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Dawson K, Pfaller M, et al. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother. 1995;39(2):314–319.
   PubMed Web of Science ®Google Scholar
• Seyedmousavi S, Bruggemann RJ, Meis JF, et al. Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model. Antimicrob Agents Chemother. 2015 May;59(5):2855–2866.
   PubMed Web of Science ®Google Scholar
• Buil JB, Bruggemann RJM, Wasmann RE, et al. Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs. J Antimicrob Chemother. 2018 Jan 1;73(1):134–142.
   PubMed Web of Science ®Google Scholar
• Buil JB, van der Lee HAL, Rijs A, et al. Single-center evaluation of an agar-based screening for azole resistance in Aspergillus fumigatus by using VIPcheck. Antimicrob Agents Chemother. 2017 Dec;61(12):e01250–17.
   PubMed Web of Science ®Google Scholar
• Bertuzzi M, van Rhijn N, Krappmann S, et al. On the lineage of Aspergillus fumigatus isolates in common laboratory use. Med Mycol. 2020;59(1):7–13.
   Web of Science ®Google Scholar
• van Rhijn N, Furukawa T, Zhao C, et al. Development of a marker-free mutagenesis system using CRISPR-Cas9 in the pathogenic mould Aspergillus fumigatus. Fungal Genet Biol. 2020;145:103479.
   PubMed Web of Science ®Google Scholar
• Peng D, Tarleton R. EuPaGDT: a web tool tailored to design CRISPR guide RNAs for eukaryotic pathogens. Microb Genom. 2015 Oct;1(4):e000033.
   PubMed Web of Science ®Google Scholar
• Seyedmousavi S, Mouton JW, Melchers WJG, et al. In vivo efficacy of liposomal amphotericin B against wild-type and azole-resistant Aspergillus fumigatus isolates in two different immunosuppression models of invasive aspergillosis. Antimicrob Agents Chemother. 2017 Jun;61(6):e02479-16.
   PubMed Web of Science ®Google Scholar
• Paisley D, Robson GD, Denning DW. Correlation between in vitro growth rate and in vivo virulence in Aspergillus fumigatus. Med Mycol. 2005 Aug;43(5):397–401.
   PubMed Web of Science ®Google Scholar
• Samson RA, Visagie CM, Houbraken J, et al. Phylogeny, identification and nomenclature of the genus aspergillus. Stud Mycol. 2014 Jun;78:141–173.
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Mavridou E, Mortensen KL, et al. Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS One. 2010;5(4):e10080.
   PubMed Web of Science ®Google Scholar
• Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis. 2009 Jul;15(7):1068–1076.
   PubMed Web of Science ®Google Scholar
• Ballard E, Melchers WJG, Zoll J, et al. In-host microevolution of Aspergillus fumigatus: a phenotypic and genotypic analysis. Fungal Genet Biol. 2018 Apr;113:1–13.
   PubMed Web of Science ®Google Scholar
• Bongomin F, Harris C, Hayes G, et al. Twelve-month clinical outcomes of 206 patients with chronic pulmonary aspergillosis. PLoS One. 2018;13(4):e0193732.
   PubMed Web of Science ®Google Scholar
• Dudakova A, Spiess B, Tangwattanachuleeporn M, et al. Molecular tools for the detection and deduction of azole antifungal drug resistance phenotypes in Aspergillus species. Clin Microbiol Rev. 2017 Oct;30(4):1065–1091.
   PubMed Web of Science ®Google Scholar
• D'Enfert C, Diaquin M, Delit A, et al. Attenuated virulence of uridine-uracil auxotrophs of Aspergillus fumigatus. Infect Immun. 1996 Oct;64(10):4401–4405.
   PubMed Web of Science ®Google Scholar
• Retallack DM, Heinecke EL, Gibbons R, et al. The URA5 gene is necessary for histoplasma capsulatum growth during infection of mouse and human cells. Infect Immun. 1999;67(2):624–629.
   PubMed Web of Science ®Google Scholar
• Noble SM, Johnson AD. Strains and strategies for large-scale gene deletion studies of the diploid human fungal pathogen Candida albicans. Eukaryot Cell. 2005 Feb;4(2):298–309.
   PubMedGoogle Scholar
• de Gontijo FA, Pascon RC, Fernandes L, et al. The role of the de novo pyrimidine biosynthetic pathway in Cryptococcus neoformans high temperature growth and virulence. Fungal Genet Biol. 2014 Sep;70:12–23.
   PubMed Web of Science ®Google Scholar
• van Rhijn N, Hemmings S, Valero C, et al. Olorofim and the azoles are antagonistic in A. fumigatus and functional genomic screens reveal mechanisms of cross resistance. bioRxiv. 2021:2021.11.18.469075.
   Google Scholar
• Escribano P, Recio S, Peláez T, et al. In vitro acquisition of secondary azole resistance in Aspergillus fumigatus isolates after prolonged exposure to itraconazole: presence of heteroresistant populations. Antimicrob Agents Chemother. 2012 Jan;56(1):174–178.
   PubMed Web of Science ®Google Scholar
• da Silva Ferreira ME, Capellaro JL, dos Reis Marques E, et al. In vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance. Antimicrob Agents Chemother. 2004;48(11):4405–4413.
   PubMed Web of Science ®Google Scholar
• Mellado E, Aufauvre-Brown A, Gow NA, et al. The Aspergillus fumigatus chsC and chsG genes encode class III chitin synthases with different functions. Mol Microbiol. 1996 May;20(3):667–679.
   PubMed Web of Science ®Google Scholar
• Verweij PE, Zhang J, Debets AJM, et al. In-host adaptation and acquired triazole resistance in Aspergillus fumigatus: a dilemma for clinical management. Lancet Infect Dis. 2016 Nov;16(11):e251–e260.
   PubMedGoogle Scholar